Print this page
-
Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients with Advanced Solid Tumors.
Protocol: 052409Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients with Advanced Solid Tumors.
Protocol: 052409Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1/1b Study of IAM1363 in Participants with Advanced Cancers Harboring HER2 Alterations.
Protocol: 052501Principal Investigator:
- Coral Omene
Applicable Disease Sites: Any Site -
A Phase 1/1b Study of IAM1363 in Participants with Advanced Cancers Harboring HER2 Alterations.
Protocol: 052501Principal Investigator:
- Coral Omene
Applicable Disease Sites: Any Site -
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of GSK5764227 in Participants with Advanced Solid Tumors.
Protocol: 052503Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of GSK5764227 in Participants with Advanced Solid Tumors.
Protocol: 052503Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Dose Escalation and Expansion Study of XB371 Administered in Participants with Locally Advanced or Metastatic Solid Tumors
Protocol: 052504Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Dose Escalation and Expansion Study of XB371 Administered in Participants with Locally Advanced or Metastatic Solid Tumors
Protocol: 052504Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1/2, Open-Label, Multicenter, Dose-Escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants with Advanced Solid Tumors.
Protocol: 052505Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1/2, Open-Label, Multicenter, Dose-Escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants with Advanced Solid Tumors.
Protocol: 052505Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of MK-4716 as Monotherapy and as Part of Combination Therapy in Participants with KRAS-Altered Advanced or Metastatic Solid Tumors.
Protocol: 052506Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of MK-4716 as Monotherapy and as Part of Combination Therapy in Participants with KRAS-Altered Advanced or Metastatic Solid Tumors.
Protocol: 052506Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with Locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Tumors.
Protocol: 052509Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Esophagus
Lung
Other Digestive Organ
Pancreas
Thyroid -
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with Locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Tumors.
Protocol: 052509Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Esophagus
Lung
Other Digestive Organ
Pancreas
Thyroid -
A Phase 1/Randomized Phase 2 Study of M3814 (peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma.
Protocol: 072403Principal Investigator:
- Matthew Deek
Applicable Disease Sites: Pancreas -
A Phase 1/Randomized Phase 2 Study of M3814 (peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma.
Protocol: 072403Principal Investigator:
- Matthew Deek
Applicable Disease Sites: Pancreas